JPH06508816A - (s)(+)−2−エトキシ−4−[n−[1−(2−ピペリジノ−フェニル)−3−メチル−1−ブチル〕アミノカルボニルメチル〕−安息香酸、この化合物を含む医薬組成物及びその調製方法 - Google Patents
(s)(+)−2−エトキシ−4−[n−[1−(2−ピペリジノ−フェニル)−3−メチル−1−ブチル〕アミノカルボニルメチル〕−安息香酸、この化合物を含む医薬組成物及びその調製方法Info
- Publication number
- JPH06508816A JPH06508816A JP3511056A JP51105691A JPH06508816A JP H06508816 A JPH06508816 A JP H06508816A JP 3511056 A JP3511056 A JP 3511056A JP 51105691 A JP51105691 A JP 51105691A JP H06508816 A JPH06508816 A JP H06508816A
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- tables
- formula
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (11)
- 1.(S)(+)−2−エトキシ−4−[N−[1−(2−ピペリジノーフェニ ル)−3−メチル−1−ブチル]アミノカルボニルメチル]−安息香酸及び有機 または無機の酸または塩基とのその塩。
- 2.実質的に光学上純粋である請求の範囲第1項に記載の化合物。
- 3.少なくともee=95%の光学純度を有する請求の範囲第2項に記載の化合 物。
- 4.少なくともee=98%の光学純度を有する請求の範囲第2項に記載の化合 物。
- 5.請求の範囲第1項〜第4項に記載の化合物と有機または無機の酸または塩基 との生理学上許される塩。
- 6.一種以上の不活性な担体及び/または希釈剤と一緒に請求の範囲第1項〜第 4項に記載の化合物または請求の範囲第5項に記載の生理学上許される塩を含む 医薬組成物。
- 7.真性糖尿病を治療するための請求の範囲第1項〜第4項に記載の化合物また は請求の範囲第5項に記載のその生理学上許される塩の使用。
- 8.請求の範囲第1項〜第4項に記載の化合物または請求の範囲第5項に記載の 生理学上許される塩を非化学的方法により一種以上の不活性な担体及び/または 希釈剤に混入することを特徴とする請求の範囲第6項に記載の医薬組成物の調製 方法。
- 9.a)式 ▲数式、化学式、表等があります▼(I)の(S)−アミンを一般式 ▲数式、化学式、表等があります▼(II)(式中、 Wはカルボキシ基または保護基により保護されたカルボキシ基を表す)のカルボ ン酸または必要によりその反応混合物中で調製されてもよいその反応誘導体と反 応させ、続いて、必要により、使用した保護基を開裂し、またはb)一般式 ▲数式、化学式、表等があります▼(III)(式中、 Aは加水分解、熱分解または水添分解によりカルボキシ基に変換し得る基を表す ) の(S)−化合物を開裂し、または c)一般式 ▲数式、化学式、表等があります▼(IV)(式中、 W′はカルボキシ基または合計2〜5個の炭素原子を有するアルコキシカルボニ ル基を表し、そのアルコキシ基のアルキル部分はフェニル基により置換されてい てもよい) の(S)−化合物を一般式 Z−CH2−CH3(V) (式中、 Zは求核的に交換可能な基を表し、または隣接水素原子と一緒になって、ジアゾ 基を表す) の化合物と反応させ、続いて、必要により、こうして得られた化合物を加水分解 または水添分解し、または d)一般式 ▲数式、化学式、表等があります▼(VI)(式中、 W′はカルボキシ基または合計2〜5個の炭素原子を有するアルコキシカルボニ ル基を表し、そのアルコキシ基のアルキル部分はフェニル基により置換されてい てもよく、かつ Yは式 ▲数式、化学式、表等があります▼▲数式、化学式、表等があります▼または▲ 数式、化学式、表等があります▼の基を表す) の化合物を鏡像選択的に還元し、続いて、必要により、こうして得られた化合物 を加水分解し、または e)一般式 ▲数式、化学式、表等があります▼(VII)(式中、 W′′は酸化によりカルボキシ基に変換し得る基を表す)の(S)−化合物を酸 化し、または f)所望の量の一般式 ▲数式、化学式、表等があります▼(VIII)の(S)−鏡像体と、所望の量 の一般式▲数式、化学式、表等があります▼(IX)(式中、 W′はカルボキシ基または合計2〜5個の炭素原子を有するアルコキシカルボニ ル基を表し、そのアルコキシ基のアルキル部分はフェニル基により置換されてい てもよい) の(R)−鏡像体からなる混合物を分離し、そしてこうして得られた化合物を、 必要により、再結晶により更に高い鏡像体純度を有する化合物に変換し、ここで エタノール/水(2/1)による結晶化により130〜131℃の融点を有する 高融点形態を生じ、また石油エーテル/トルエン(5/3)による結晶化により 99〜101℃の融点を有する低融点形態を生じそしてこうして得られた化合物 を有機または無機の酸または塩基とのその塩、特に生理学上許される塩に変換す ることを特徴とする請求の範囲第1項〜第5項に記載の新規化合物の調製方法。
- 10.(S)−3−メチル−1−(2−ピペリジノーフェニル)−1−ブチルア ミン及びその酸付加塩。
- 11.一般式 ▲数式、化学式、表等があります▼(III)▲数式、化学式、表等があります ▼(IV)及び ▲数式、化学式、表等があります▼(VII)(式中、 Aは加水分解、熱分解または水添分解によりカルボキシ基に変換し得る基を表し 、 W′はカルボキシ基または合計2〜5個の炭素原子を有するアルコキシカルボニ ル基を表し、そのアルコキシ基のアルキル部分はフェニル基により置換されてい てもよく、かつ W′′は酸化によりカルボキシ基に変換し得る基を表す)の新規化合物、及びそ の付加塩。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1991/001147 WO1993000337A1 (de) | 1991-06-21 | 1991-06-21 | (s)(+)-2-äthoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoesäure |
SG1996002715A SG43036A1 (en) | 1991-06-21 | 1991-06-21 | (S) (+) -2-ethoxy-4-[N-[1-(2-piperidino-phenyl)-3-methyl- 1-buthyl]aminocarbony methyl] - benzoic a cid |
CA002111851A CA2111851C (en) | 1991-06-21 | 1991-06-21 | (s)(+)-2-ethoxy-4-[n-{1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid |
CN91104984A CN1048722C (zh) | 1991-06-21 | 1991-07-22 | (s)(+)-2-乙氧基-4-[n-[1-(2-哌啶子基-苯基)-3-甲基-1-丁基]氨基羰基甲基]苯甲酸,含该化合物的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06508816A true JPH06508816A (ja) | 1994-10-06 |
JP2921982B2 JP2921982B2 (ja) | 1999-07-19 |
Family
ID=36781542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3511056A Expired - Lifetime JP2921982B2 (ja) | 1991-06-21 | 1991-06-21 | (s)(+)−2−エトキシ−4−[n−[1−(2−ピペリジノ−フェニル)−3−メチル−1−ブチル〕アミノカルボニルメチル〕−安息香酸、この化合物を含む医薬組成物及びその調製方法 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0589874B1 (ja) |
JP (1) | JP2921982B2 (ja) |
CN (1) | CN1048722C (ja) |
AU (1) | AU660930B2 (ja) |
FI (1) | FI106027B (ja) |
NO (2) | NO303687B1 (ja) |
SG (1) | SG43036A1 (ja) |
WO (1) | WO1993000337A1 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002500677A (ja) | 1997-06-13 | 2002-01-08 | ノボ ノルディスク アクティーゼルスカブ | 新規niddm療法 |
IN192862B (ja) * | 1999-11-16 | 2004-05-22 | Ranbaxy Lab Ltd | |
AR033390A1 (es) | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
AU2003217676B2 (en) | 2002-02-22 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Active agent delivery systems and methods for protecting and administering active agents |
WO2004018442A1 (en) * | 2002-08-23 | 2004-03-04 | Dr. Reddy's Laboratories Limited | Crystalline and amorphous forms of (s) -repaglinide and the processes for preparation thereof |
US7915421B2 (en) | 2003-05-14 | 2011-03-29 | Cilag Ltd. | Method for preparing phenyl acetic acid derivatives |
AU2003237595A1 (en) * | 2003-05-26 | 2004-12-13 | Biocon Limited | Process for the preparation of s(+)-2-ethoxy-4-(n-{1-(2-piperidinophelyl)-3-methyl-1- butyl} aminocarbonylmethyl)benzoic acid derivatives |
WO2005021524A1 (en) * | 2003-08-28 | 2005-03-10 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous form of repaglinide |
CN1305863C (zh) * | 2004-12-27 | 2007-03-21 | 浙江大学 | (s)-异丙基-(2-哌啶)苯基-甲基胺的合成方法 |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
FR2898894B1 (fr) * | 2006-03-24 | 2008-06-06 | Genfit Sa | Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations |
US7763607B2 (en) * | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
WO2008051902A2 (en) | 2006-10-20 | 2008-05-02 | Cpd, Llc | Method of restoring the incretin effect |
US8101769B2 (en) | 2007-02-15 | 2012-01-24 | Actavis Group Ptc Ehf | Process for preparing ethyl (S)-2-ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonyl methyl]benzoate and use thereof for the preparation of Repaglinide |
WO2009004485A2 (en) * | 2007-06-06 | 2009-01-08 | Actavis Group Ptc Ehf | Repaglinide substantially free of dimer impurity |
EP2019097A1 (en) | 2007-07-25 | 2009-01-28 | Aurobindo Pharma Limited | Process for preparing (alphaS)-alpha-(2-methylpropyl)-2-(1-piperidinyl)benzenemethanamine |
DE102008046995B4 (de) * | 2008-09-12 | 2010-08-26 | Stada Arzneimittel Ag | 2-Ethoxy-benzoesäurederivat |
EP2177221A1 (en) | 2008-10-20 | 2010-04-21 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of substantially optically pure Repaglinide and precursors thereof |
JP5659224B2 (ja) | 2009-05-15 | 2015-01-28 | ノバルティス アーゲー | アルドステロンシンターゼ阻害剤としてのアリールピリジン |
CN102459247B (zh) | 2009-05-15 | 2014-09-17 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的苯并噁唑酮衍生物 |
SG176010A1 (en) | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
AU2010251967B9 (en) | 2009-05-28 | 2014-04-03 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
ES2663351T3 (es) | 2009-11-17 | 2018-04-12 | Novartis Ag | Derivados de aril-piridina como inhibidores de la aldosterona sintasa |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
JP5575913B2 (ja) | 2009-11-30 | 2014-08-20 | ノバルティス アーゲー | アルドステロン合成酵素阻害剤としてのイミダゾール誘導体 |
EP2364977A1 (en) | 2010-01-26 | 2011-09-14 | Reuter Chemische Apparatebau KG | Process for the enantiomeric enrichment of 3-methyl-1-(2-piperidinophenyl)-1-butylamine |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
CN102267959B (zh) * | 2011-07-06 | 2013-05-01 | 海南锦瑞制药股份有限公司 | 一种瑞格列奈晶体、其制备方法及含有该晶体的固体口服制剂 |
CN103012319B (zh) * | 2011-09-20 | 2015-06-10 | 浙江九洲药业股份有限公司 | 瑞格列奈中间体的合成工艺改进 |
CN102584743A (zh) * | 2011-12-28 | 2012-07-18 | 中国药科大学 | 对二甲氨基吡啶瑞格列奈共晶 |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
JP6295277B2 (ja) | 2013-02-14 | 2018-03-14 | ノバルティス アーゲー | Nep(中性エンドペプチダーゼ)阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体 |
AU2014293387B2 (en) | 2013-07-25 | 2017-04-20 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
KR20160031551A (ko) | 2013-07-25 | 2016-03-22 | 노파르티스 아게 | 심부전의 치료를 위한 시클릭 폴리펩티드 |
US10034871B2 (en) | 2014-11-07 | 2018-07-31 | Regents Of The University Of Minnesota | Salts and compositions useful for treating disease |
EA201791668A1 (ru) | 2015-01-23 | 2017-11-30 | Новартис Аг | Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада |
WO2018034627A1 (en) | 2016-08-18 | 2018-02-22 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Pharmaceutical composition of antidiabetic tablet |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3347565A1 (de) * | 1983-12-30 | 1985-07-11 | Thomae Gmbh Dr K | Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
-
1991
- 1991-06-21 SG SG1996002715A patent/SG43036A1/en unknown
- 1991-06-21 JP JP3511056A patent/JP2921982B2/ja not_active Expired - Lifetime
- 1991-06-21 EP EP91911959A patent/EP0589874B1/de not_active Expired - Lifetime
- 1991-06-21 AU AU80781/91A patent/AU660930B2/en not_active Expired
- 1991-06-21 WO PCT/EP1991/001147 patent/WO1993000337A1/de active IP Right Grant
- 1991-07-22 CN CN91104984A patent/CN1048722C/zh not_active Expired - Lifetime
-
1993
- 1993-12-20 FI FI935724A patent/FI106027B/fi not_active IP Right Cessation
- 1993-12-20 NO NO934726A patent/NO303687B1/no not_active IP Right Cessation
-
1999
- 1999-07-20 NO NO1999017C patent/NO1999017I1/no unknown
Also Published As
Publication number | Publication date |
---|---|
JP2921982B2 (ja) | 1999-07-19 |
WO1993000337A1 (de) | 1993-01-07 |
AU660930B2 (en) | 1995-07-13 |
NO303687B1 (no) | 1998-08-17 |
EP0589874B1 (de) | 1999-09-08 |
CN1068820A (zh) | 1993-02-10 |
FI106027B (fi) | 2000-11-15 |
EP0589874A1 (de) | 1994-04-06 |
NO934726D0 (no) | 1993-12-20 |
SG43036A1 (en) | 1997-10-17 |
CN1048722C (zh) | 2000-01-26 |
AU8078191A (en) | 1993-01-25 |
FI935724A (fi) | 1993-12-20 |
NO1999017I1 (no) | 1999-07-20 |
NO934726L (no) | 1993-12-20 |
FI935724A0 (fi) | 1993-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06508816A (ja) | (s)(+)−2−エトキシ−4−[n−[1−(2−ピペリジノ−フェニル)−3−メチル−1−ブチル〕アミノカルボニルメチル〕−安息香酸、この化合物を含む医薬組成物及びその調製方法 | |
US9452169B2 (en) | Substituted diketopiperazines and their use as oxytocin antagonists | |
WO2000053600A1 (fr) | Derives piperidiniques | |
EP2475645B1 (en) | 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents | |
JPS61151172A (ja) | インドール、その製造方法及びそれを含有する製薬組成物 | |
EP0929550A1 (fr) | DERIVES DE $i(N)-(BENZOTHIAZOL-2-YL)PIPERIDINE-1-ETHANAMINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE | |
JP3786983B2 (ja) | ピロリジノン誘導体 | |
CA2111851C (en) | (s)(+)-2-ethoxy-4-[n-{1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid | |
KR100496720B1 (ko) | (s)(+)-2-에톡시-4[n-[1-(2-피페리디노페닐)-3-메틸-1-부틸]아미노카보닐메틸]-벤조산을함유하는당뇨병치료제 | |
EP0965591A1 (de) | (S)-3-Methyl-1-(2-piperidino-phenyl)-1-butylamin, dessen Salze, Herstellung und Verwendung bei der Langzeittherapie des Diabetes mellitus | |
RU1831481C (ru) | (S)(+)-2-этокси-4- @ N-[1-(2-пиперидино-фенил)-3-метил-1-бутил]-аминокарбонилметил @ -бензойна кислота или ее гидрат, или фармацевтически переносима соль, обладающие гипогликемическим действием | |
IE990936L (en) | Benzoic Acid Derivative | |
JPS61148144A (ja) | フエニル酪酸誘導体 | |
SI9111136A (en) | (S)-(+)-2-ethoxy-4-/N-/1-(2-piperidino-phenyl)-3-methyl-1-butyl/ aminocarbonylmethyl/-benzoic acid, pharmaceuticals containing this compaund and processes for their preparation | |
IE85730B1 (en) | Benzoic acid derivative | |
JP2000507562A (ja) | ジメチル―置換シクロヘキサンジエン誘導体 | |
HRP940769A2 (en) | (s)(+)-2-ethoxy-4-(n-(1-(2-piperidinophenyl)-3-methyl-1-butyl)-aminocarbonylmethyl)benzoic acid, medicines containing them, that compound and processes for the preparation thereof | |
SK128093A3 (en) | (s) (+)-2 ethoxy-4-(n-(1-(2-(n-piperidinyl)-phenyl)-3-methyl- -1-butyl) aminocarbonylmethyl) benzoic acid | |
CZ280430B6 (cs) | Kyselina (S)(+)-2-ethoxy-4-/N-/1-(2-piperidinofenyl)-3-methyl-1-butyl/aminokarbonylmethyl/benzoová, farmaceutické prostředky s jejím obsahem, její použití a meziprodukty pro její výrobu | |
HU211240A9 (hu) | Hipoglikémiás hatással rendelkező (S)-(+)-2-etoxi-4-[{N-1-(2-piperidino-fenil)-3-metil-butil]-karbamoil}-metil·]- benzoesav vagy hidrátja vagy gyógyszerészetileg elfogadható sója Az átmeneti oltalom az igénypontra vonatkozik. | |
HU215921B (hu) | Eljárás (S)-(+)-2-etoxi-4-[{N-/1-(2-piperidino-fenil)-3-metil-butil/-karbamoil}-metil]-benzoesav és ezt tartalmazó gyógyszerkészítmények előállítására |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080430 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090430 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100430 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100430 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110430 Year of fee payment: 12 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110430 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110430 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120430 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120430 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120430 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120430 Year of fee payment: 13 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120430 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120430 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130430 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140430 Year of fee payment: 15 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |